X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MRx0518 is single strain Live Biotherapeutic Product (LBP) in development for the treatment of cancer. It is delivered as an oral capsule and stimulates the body’s immune system, directing it to produce cytokines and immune cells that are known to attack tumors.
Lead Product(s): MRx0518,Avelumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
At the end of treatment period (day 85), 50% of patients receiving MRx-4DP0004 reduced their use of SABA rescue medication as compared to 18.8% for patients receiving placebo.
Lead Product(s): MRx-4DP0004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRx-4DP0004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with solid tumors progressed on a prior immune checkpoint inhibitor, the renal cell carcinoma group has met its primary efficacy endpoint ahead of enrollment completion.
Lead Product(s): MRx0518,Pembrolizumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
IND clearance marks the expansion of the comany's pipeline single strain Live Biotherapeutics of MRx0005 and MRx0029 in development for the treatment of neurodegenerative conditions such as Parkinson’s disease via the gut-brain axis.
Lead Product(s): MRx0005
Therapeutic Area: Neurology Product Name: MRx0005
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
MRx-4DP0004 is an oral, immunomodulatory, single strain live biotherapeutic product, that has been demonstrated to reduce airway inflammation in the treatment of patients with asthma.
Lead Product(s): MRx-4DP0004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRx-4DP0004
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
Results demonstrate changes in gut microbiome structure following administration of Blautix (Blautia Hydrogenotrophica) in both IBS-C and IBS-D patients.
Lead Product(s): Blautia Hydrogenotrophica
Therapeutic Area: Gastroenterology Product Name: Blautix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
One presentation details baseline biomarkers associated with clinical benefit from MRx0518, indicating a potential tumor biomarker predictive of response.
Lead Product(s): MRx0518,Pembrolizumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
In Phase II trial, where Blautix demonstrated signals of clinical activity in both IBS-C and IBS-D, and a highly favorable safety and tolerability profile.
Lead Product(s): Blautia Hydrogenotrophica
Therapeutic Area: Gastroenterology Product Name: Blautix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
4D pharma intends to commence a clinical trial in 2021 to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
Details:
4D pharma intends to commence a clinical trial to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.
Lead Product(s): MRx0518,Avelumab
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
